Dailong Li
Wuhan, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
Efficacy and safety of anlotinib plus EGFR-TKI for advanced non-small cell lung cancer with EGFR mutations: A meta-analysis of randomized controlled trials.
Journal: Medicine
Published: August 04, 2025
MYB Proto-Oncogene Like 2 Promotes the Growth of Renal Carcinoma by Attenuating Endoplasmic Reticulum Stress and Activating Lipid Rafts.
Journal: Archivos espanoles de urologia
Published: July 11, 2025
The long-term efficacy and safety of apatinib are inferior to sorafenib in the first-line treatment of advanced hepatocellular carcinoma: A systematic review and meta-analysis.
Journal: Medicine
Published: January 19, 2024
Sorafenib exhibits lower toxicity and comparable efficacy to sunitinib as a first-line treatment for metastatic renal cell carcinoma: A systematic review and meta-analysis.
Journal: Medicine
Published: September 08, 2023
Efficacy and safety of transarterial chemoembolization plus lenvatinib in the treatment of advanced hepatocellular carcinoma: A meta-analysis.
Journal: Medicine
Published: September 01, 2023
Efficacy and safety of Kanglaite plus EGFR-TKI in the treatment of advanced non-small cell lung cancer: A meta-analysis of 13 RCTs.
Journal: Medicine
Published: December 23, 2022
Efficacy and safety of icotinib in the treatment of advanced EGFR mutation-positive nonsmall cell lung cancer: A meta-analysis of randomized controlled trials.
Journal: Medicine
Published: December 09, 2022
The effect of adjuvant chemoradiotherapy on survival after R0 resection for stage III-N2 nonsmall cell lung cancer: A meta-analysis.
Journal: Medicine
Published: July 15, 2022
Sintilimab combined with apatinib plus capecitabine in the treatment of unresectable hepatocellular carcinoma: A prospective, open-label, single-arm, phase II clinical study.
Journal: Frontiers in immunology
Published: May 14, 2022
Last Updated: 09/26/2026